Genomic epidemiology of CVA10 in Guangdong, China, 2013–2021

Huimin Lian,Lina Yi,Ming Qiu,Baisheng Li,Limei Sun,Huiling Zeng,Biao Zeng,Fen Yang,Haiyi Yang,Mingda Yang,Chunyan Xie,Lin Qu,Huifang Lin,Pengwei Hu,Shaojian Xu,Hanri Zeng,Jing Lu
DOI: https://doi.org/10.1186/s12985-024-02389-9
IF: 5.916
2024-06-02
Virology Journal
Abstract:Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness primarily affecting children globally. A significant epidemiological transition has been noted in mainland China, characterized by a substantial increase in HFMD cases caused by non-Enterovirus A71 (EV-A71) and non-Coxsackievirus A16 (CVA16) enteroviruses (EVs). Our study conducts a retrospective examination of 36,461 EV-positive specimens collected from Guangdong, China, from 2013 to 2021. Epidemiological trends suggest that, following 2013, Coxsackievirus A6 (CVA6) and Coxsackievirus A10 (CVA10) have emerged as the primary etiological agents for HFMD. In stark contrast, the incidence of EV-A71 has sharply declined, nearing extinction after 2018. Notably, cases of CVA10 infection were considerably younger, with a median age of 1.8 years, compared to 2.3 years for those with EV-A71 infections, possibly indicating accumulated EV-A71-specific herd immunity among young children. Through extensive genomic sequencing and analysis, we identified the N136D mutation in the 2 A protein, contributing to a predominant subcluster within genogroup C of CVA10 circulating in Guangdong since 2017. Additionally, a high frequency of recombination events was observed in genogroup F of CVA10, suggesting that the prevalence of this lineage might be underrecognized. The dynamic landscape of EV genotypes, along with their potential to cause outbreaks, underscores the need to broaden surveillance efforts to include a more diverse spectrum of EV genotypes. Moreover, given the shifting dominance of EV genotypes, it may be prudent to re-evaluate and optimize existing vaccination strategies, which are currently focused primarily target EV-A71.
virology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is about the changes in epidemiology and genetic diversity of hand - foot - mouth disease (HFMD) in Guangdong province, China from 2013 to 2021. Specifically, the paper focuses on the following aspects: 1. **Changes in epidemiological trends**: - The paper explores the epidemic trend that since 2013, the main pathogens causing hand - foot - mouth disease have shifted from EV - A71 and CVA16 to other non - EV - A71/CVA16 enteroviruses, especially CVA10. - The study found that CVA10 reached its peak in 2018 and became one of the main pathogenic strains. 2. **Changes in age distribution**: - The paper analyzed the age distribution of patients infected with different pathogens and found that the median age of patients infected with CVA10 was significantly lower than that of patients infected with EV - A71 (1.8 years vs 2.3 years), which may reflect the enhanced immunity to EV - A71 in young children. 3. **Genomic diversity and recombination events**: - Through extensive genomic sequencing and analysis, the study revealed the genetic diversity of CVA10 in different genomic regions and found high - frequency recombination events, especially in the F genomic group of CVA10. - In particular, the study found the occurrence of a specific mutation (N136D) in the 2A protein, and this mutation may be related to the increased prevalence of CVA10. 4. **Public health significance**: - The paper emphasizes the importance of continuous monitoring of hand - foot - mouth disease pathogens, especially the need to expand the monitoring scope to include more diverse enterovirus genotypes. - In view of the dynamic changes of pathogens, the existing vaccine strategies may need to be re - evaluated and optimized to cope with the new epidemic trends. In conclusion, through detailed epidemiological and genomic analysis, this paper reveals the complex changes of hand - foot - mouth disease pathogens and provides important scientific basis for future disease prevention and control and vaccine research and development.